take note please

This was a directors announcement stating the hospitals are awaiting supply.Confirmed at the meeting .Also that clinicians are awaiting supply outside of these hospitals ITS ALL GO. GO GOHe also reported that testing of the facility, which was under way when he left Russia,
has now been successfully completed more than three weeks ahead of schedule. This
process, which was very thorough and well planned, has proven extremely valuable. It
revealed an ability to tune the plant in a way that increases its production capacity from a
planned 20kg of Bioeffective® R per month, to around 40kg per month, without any
material additional capital expenditure.
This increased production capacity translates into a total of 10,000 courses of Ropren®
per month, or 120,000 courses per year.
The Board is also pleased to report that Dr Victoria Gorbacheva has now joined Solagran
as General Manager, Solagran Russia. Dr Gorbacheva has brought with her a five
person team with which to manage the marketing of Ropren® in St Petersburg and
Moscow.
At this stage, there are nine hospitals across these two cities that are waiting to receive
their initial supply of Ropren®. Firm orders will be confirmed when pricing has been
finalised in mid May and will be announced to the market at that time. Marketing to
senior clinicians outside these nine institutions will also commence at that time. GO.